Vaccitech Newsroom

Vaccitech, a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases (ID), announced today that it has appointed Bill Enright as its new Chief Executive Officer (CEO). Mr. Enright succeeds Tom Evans, MD who...

To manage and maintain oversight for all study activities allocated. This will involve team leadership, management of clinical sites and vendors, budgeting, adherence to internal SOPs, ICH GCP and applicable regulations as well as other tasks relevant to coordinating...

Vaccitech, a clinical-stage T cell immunotherapy company developing viral vectors as vaccines to treat and prevent Cancer and Infectious Diseases, announces today that it has appointed Mariem Charafeddine as Chief Medical Officer. Mariem brings over 15 years’...

Vaccitech initiates Phase 2b clinical studies for its MVA-NP+M1 universal flu vaccine (VTP-100) in Belgium and completes recruitment in Australia Oxford, United Kingdom – 5 June 2019: Vaccitech Ltd. announces that it has administered its pandemic universal influenza A...

AGE1.CR® Duck Cell Line - Safe and Well tolerated for Large-Scale Production Berlin, Germany, and Oxford, United Kingdom, May 15th, 2019: ProBioGen AG, a premier German service & technology provider for complex biologics and Vaccitech, Ltd., a spin-out company...

Contract includes funding to conduct one of the largest influenza A challenge studies   Vaccitech announced today that it has been awarded a contract valued at $8.6 million from the Biomedical Advanced Research and Development Authority (BARDA), a component of...

To assist with the coordination and oversight of cross-functional activities to support the Vaccitech portfolio of research and development programmes. All activities carried out within allocated time, and agreed costs and in accordance with quality requirements,...

Vaccitech will progress existing vaccine programs and the collaboration will combine Vaccitech’s know-how with GeneMatrix’s clinical network. Oxford, UK and Seoul, South Korea Vaccitech, a clinical stage developer of a universal flu vaccine and other vaccine-related...

Vaccitech has taken the decision not to proceed with season 2 of the current FLU007 (Invictus) study due to the changes recommended by the UK Government which directed the NHS to use FLUAD (adjuvanted TIV) vaccine in the 65 year old and over population in the 2018/19...

CEPI Awards Contract Worth Up To USD$19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines